Clinical trial
Phase II Laser Focal Therapy of Prostate Cancer
NCT02243033 · HALO Diagnostics, Industry · Active, not recruiting
Key facts
| NCT number | NCT02243033 |
|---|---|
| Title | Phase II Laser Focal Therapy of Prostate Cancer |
| Official title | A Phase II Study to Evaluate Outpatient Magnetic Resonance Image-guided Laser Focal Therapy for Prostate Cancer, a 20-year Survival Study |
| Acronym | LITT or FLA |
| Lead sponsor | HALO Diagnostics, Industry |
| Status | Active, not recruiting |
| Study type | Observational |
| Conditions | Prostate Cancer |
| Intervention type | Device |
| Interventions | MR-guided laser focal therapy |
| Enrollment | 1,000 |
| Start date | May 1, 2016 |
| Primary completion | May 1, 2036 |
| Completion | Nov 1, 2036 |
| First posted | Sep 17, 2014 |
| Last update posted | Mar 25, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: